All Outputs (91)

British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025 (2025)
Journal Article
Moran, G. W., Gordon, M., Sinopolou, V., Radford, S. J., Darie, A.-M., Kumar Vuyyuru, S., Alrubaiy, L., Arebi, N., Blackwell, J., Butler, T. D., Chew, T., Cooney, R., De Marco, G., Din, S., Din, S., Feakins, R., Gasparetto, M., Gordon, H., Hansen, R., Kok, K. B., …IBD guideline development group. (2025). British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. Gut, 74(Suppl 2), s1-s101. https://doi.org/10.1136/gutjnl-2024-334395

In response to recent advancements in inflammatory bowel disease (IBD) management, the British Society of Gastroenterology (BSG) Clinical Services and Standards Committee (CSSC) has commissioned the BSG IBD section to update its guidelines, last revi... Read More about British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025.

Inter- and intra-observer variability of software quantified bowel motility measurements of small bowel Crohn’s disease: findings from the MOTILITY trial (2025)
Journal Article
Hameed, M., Plumb, A. A., Chowdhury, K., Ahmed, N., Rahman, S., Bhatnagar, G., Thomson, E., Mohsin, M., Holmes, J., Halligan, S., Taylor, S. A., on behalf of the MOTILITY trial investigators, Cetroni, A., Kaur, J., & Moran, G. (2025). Inter- and intra-observer variability of software quantified bowel motility measurements of small bowel Crohn’s disease: findings from the MOTILITY trial. Insights into Imaging, 16(1), Article 111. https://doi.org/10.1186/s13244-025-01978-8

Objectives
Motility magnetic resonance imaging (mMRI) is a potential marker of disease activity of small bowel Crohn’s disease (SBCD), but there is limited data on its reproducibility. We assessed inter- and intra-observer agreement of small bowel m... Read More about Inter- and intra-observer variability of software quantified bowel motility measurements of small bowel Crohn’s disease: findings from the MOTILITY trial.

Developing IBD Outcome Effect Size Thresholds to Inform Research, Guidelines, and Clinical Decisions (2025)
Journal Article
Gordon, M., Shaban, N., Sinopoulou, V., Vuyyuru, S., Radford, S., Magro, F., Armuzzi, A., Peyrin-Biroulet, L., Jairath, V., & Moran, G. (2025). Developing IBD Outcome Effect Size Thresholds to Inform Research, Guidelines, and Clinical Decisions. Inflammatory Bowel Diseases, https://doi.org/10.1093/ibd/izaf085

Background
When designing clinical trials, interpreting trial outcomes for guideline development or sharing decisions with patients in clinical practice, the clinical outcomes used and the implicit choices on what constitutes a clinically significan... Read More about Developing IBD Outcome Effect Size Thresholds to Inform Research, Guidelines, and Clinical Decisions.

Designing a multi-arm, multi-stage platform trial for venous leg ulceration – Venous leg ulcers: management and eradication, the VEIN platform study (2025)
Journal Article
Onida, S., Davies, A. H., & VEIN Platform consortium. (2025). Designing a multi-arm, multi-stage platform trial for venous leg ulceration – Venous leg ulcers: management and eradication, the VEIN platform study. NIHR Open Research, 5, Article 32. https://doi.org/10.3310/nihropenres.13847.1

Background
Venous leg ulceration (VLU) is the most severe form of venous disease and an important burden to patients and society. Many treatments for VLU exist, including wound therapies, medications, and surgical interventions. However, high-level... Read More about Designing a multi-arm, multi-stage platform trial for venous leg ulceration – Venous leg ulcers: management and eradication, the VEIN platform study.

Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial (2025)
Journal Article
Acherman, Y. I. Z., Arebi, N., Arthurs, E., Bemelman, W. A., van der Bilt, J. D. W., Braat, H., Brink, M. A., Brookes, M., Brown, J. P. Y., Brown, S. R., Buskens, C. J., Consten, E. C. J., Cooney, R., Crolla, R. M. P. H., Davies, R. J., Depla, A. C. T. M., D'Haens, G. R., Dijkgraaf, M. G. W., Doherty, G., van Duijvendijk, P., …van der Zanden, E. P. M. (2025). Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial. The Lancet Gastroenterology & Hepatology, 10(6), 550-561. https://doi.org/10.1016/S2468-1253%2825%2900026-3

Background
The appendix might have an immunomodulatory role in ulcerative colitis. Appendicectomy has been suggested as a potentially therapeutic intervention to maintain remission in ulcerative colitis. We aimed to evaluate the clinical effectivene... Read More about Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial.

Defining Radiological Healing in Perianal Fistulizing Crohn’s Disease: a TOpClass Global Expert Delphi Consensus (2025)
Journal Article
Anand, E., Devi, J., Ballard, D. H., Joshi, S., Tozer, P., Hart, A., Antoniou, A., Deepak, P., Stoker, J., Lung, P., on behalf of the TOpClass collaborative authors, & Moran, G. (2025). Defining Radiological Healing in Perianal Fistulizing Crohn’s Disease: a TOpClass Global Expert Delphi Consensus. Clinical Gastroenterology and Hepatology, https://doi.org/10.1016/j.cgh.2025.02.009

Background & Aims: Perianal fistulising Crohn's disease (pfCD) affects one-fifth of patients with Crohn's disease (CD), significantly affecting their quality of life. Magnetic resonance imaging is the gold standard for evaluating fistula healing in p... Read More about Defining Radiological Healing in Perianal Fistulizing Crohn’s Disease: a TOpClass Global Expert Delphi Consensus.

Small bowel motility quantified by cine MRI to predict longer term response in patients with Crohn’s disease commencing biological therapy: The Motility study (2025)
Journal Article
Plumb, A. A., Moran, G., Chowdhury, K., Ahmed, N., Philpott, S., Ahmad, T., Bloom, S., Hart, A., Jacobs, I., Menys, A., Mooney, P., Tolan, D., Travis, S., Bhagwanani, A., Bhatnagar, G., Boone, D., Franklin, J., Gangi-Burton, A., Hameed, M., Helbren, E., …Taylor, S. A. (in press). Small bowel motility quantified by cine MRI to predict longer term response in patients with Crohn’s disease commencing biological therapy: The Motility study. Inflammatory Bowel Diseases, https://doi.org/10.1093/ibd/izaf023

Background:
Small bowel Crohn’s Disease (SBCD) is increasingly treated with biological therapies. Predicting response or remission (RoR) for individual patients is difficult and complicates treatment strategy. We aimed to determine if motility magne... Read More about Small bowel motility quantified by cine MRI to predict longer term response in patients with Crohn’s disease commencing biological therapy: The Motility study.

Developing an adaptive platform trial for evaluation of medical treatments for Crohn’s disease (2025)
Journal Article
Noor, N. M., Radford, S. J., Choodari-Oskooei, B., Gordon, M., Hart, A. L., Hepburn, T., Juszczak, E., Lindsay, J. O., Kennedy, N. A., Parmar, M. K. B., Jairath, V., & Moran, G. W. (2025). Developing an adaptive platform trial for evaluation of medical treatments for Crohn’s disease. Nature Reviews Gastroenterology and Hepatology, 22, 364-366. https://doi.org/10.1038/s41575-025-01052-0

There is emerging interest in adaptive platform trials for inflammatory bowel disease. In this Comment, we present the results of a workshop that was convened to consider the opportunities and challenges of developing a platform trial in Crohn’s dise... Read More about Developing an adaptive platform trial for evaluation of medical treatments for Crohn’s disease.

Diffusion weighted imaging to predict longer term response in Crohn’s disease patients commencing biological therapy: Results from the MOTILITY Trial (2025)
Journal Article
Hameed, M., Taylor, S. A., Ahmed, N., Chowdhury, K., Patel, A., Helbren, E., Bhagwanani, A., Hyland, R., Bhatnagar, G., Sidhu, H., Lambie, H., Franklin, J., Mohsin, M., Thomson, E., Boone, D., Tolan, D., Rahman, S., Sakai, N. S., Moran, G. W., Hart, A., …Plumb, A. A. (2025). Diffusion weighted imaging to predict longer term response in Crohn’s disease patients commencing biological therapy: Results from the MOTILITY Trial. British Journal of Radiology, 98(1168), 527-534. https://doi.org/10.1093/bjr/tqaf013

Objectives

Predicting longer term response to biological therapy for small bowel Crohn’s disease (SBCD) is an unmet clinical need. Diffusion-weighted MR imaging (DWI) may indicate disease activity, but its predictive ability, if any, is unknown. W... Read More about Diffusion weighted imaging to predict longer term response in Crohn’s disease patients commencing biological therapy: Results from the MOTILITY Trial.

Deconditioning in quiescent Crohn’s Disease patients with heightened fatigue perception (2025)
Journal Article
McGing, J. J., Serres, S., Nicholas, R., Gupta, A., Radford, S. J., Nixon, A. V., Mallinson, J., Bradley, C., Bawden, S., Francis, S. T., Greenhaff, P. L., & Moran, G. W. (2025). Deconditioning in quiescent Crohn’s Disease patients with heightened fatigue perception. Journal of Crohn's and Colitis, 19(1), Article jjae194. https://doi.org/10.1093/ecco-jcc/

Background & Objective

IBD fatigue aetiology is poorly understood. This study quantified body composition and physical function alongside proton magnetic resonance imaging (1H MRI) and spectroscopy (31P MRS) measures of organ structure and functio... Read More about Deconditioning in quiescent Crohn’s Disease patients with heightened fatigue perception.

Association between Nutritional Status Assessed by Body Mass Index and Crohn’s Disease Phenotype: A Nation-Wide Analysis (2024)
Journal Article
Ndzo, J., Vuyyuru, S. K., Trimble, T., Yan, K., Figueredo, G., & Moran, G. W. (2024). Association between Nutritional Status Assessed by Body Mass Index and Crohn’s Disease Phenotype: A Nation-Wide Analysis. Clinical Nutrition ESPEN, 64, 290-295. https://doi.org/10.1016/j.clnesp.2024.09.033

Background & Aims:

Incidence of obesity and Crohn’s disease (CD) is increasing globally. Therefore, understanding any associations between adiposity and disease phenotype is crucial. We aimed explore the relationship between nutritional status me... Read More about Association between Nutritional Status Assessed by Body Mass Index and Crohn’s Disease Phenotype: A Nation-Wide Analysis.

ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment (2024)
Journal Article
Adamina, M., Minozzi, S., Warusavitarne, J., Buskens, C., Chaparro, M., Verstockt, B., Kopylov, U., Agrawal, M., Allocca, M., Atreya, R., Battat, R., Bettenworth, D., Bislenghi, G., Brown, S. R., Burisch, J., Casanova, M. J., Czuber-Dochan, W., de Groof, J., El-Hussuna, A., Ellul, P., …Myrelid, P. (2024). ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. Journal of Crohn's and Colitis, 18(10), 1556-1582. https://doi.org/10.1093/ecco-jcc/jjae089

This article is the second in a series of two publications on the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn's disease. The first article covers medical management; the present article address... Read More about ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.

Real-world clinical effectiveness of ustekinumab in the treatment of Crohn’s disease in the East Midlands UK (2024)
Journal Article
White, J. R., Ahmad, S., Ashraf, F., Foley, S., Din, S., Das, R. K., Charles, N. M., Pinheiro, J., Palejwala, A., Wright, P., Andiappan, M., Alexander, M., Uddin, B., Hoshen, D., Elphick, D., Qamar, T., Rezwan, N., Hamza, M. V., Glover, J., Robinson, R., …Moran, G. (2024). Real-world clinical effectiveness of ustekinumab in the treatment of Crohn’s disease in the East Midlands UK. Frontline Gastroenterology, 15(5), 359-365. https://doi.org/10.1136/flgastro-2024-102718

Objectives: To evaluate the effectiveness of ustekinumab in treating Crohn’s disease (CD) in a UK real-world setting.

Design: This was a multicentre, retrospective observational study of patients (aged ≥18 years) with CD or inflammatory bowel dise... Read More about Real-world clinical effectiveness of ustekinumab in the treatment of Crohn’s disease in the East Midlands UK.

Substantial cost savings of ultrasound-based management over magnetic resonance imaging-based management in an inflammatory bowel disease service (2024)
Journal Article
Radford, S. J., Abdul-Aema, B., Tench, C., Leighton, P., Coad, J., & Moran, G. W. (2024). Substantial cost savings of ultrasound-based management over magnetic resonance imaging-based management in an inflammatory bowel disease service. Scandinavian Journal of Gastroenterology, 59(6), 683-689. https://doi.org/10.1080/00365521.2024.2330588

Background: Imaging is used to monitor disease activity in small bowel Crohn’s disease (CD). Magnetic Resonance Enterography is often employed as a first modality in the United Kingdom for assessment and monitoring; however, waiting times, cost, pati... Read More about Substantial cost savings of ultrasound-based management over magnetic resonance imaging-based management in an inflammatory bowel disease service.

Prepublication abstract-only reports compared with full-text manuscripts for randomised controlled trials in inflammatory bowel disease: a systematic review (2024)
Journal Article
Egiz, A. M. A. M., Sinopoulou, V., Abousaleh, Gordon, M., Moran, G. W., Phlananthachai, S., Rane, A., & Al-Tameemi, A. H. A. (2024). Prepublication abstract-only reports compared with full-text manuscripts for randomised controlled trials in inflammatory bowel disease: a systematic review. BMJ Open Gastroenterology, 11(1), Article e001334. https://doi.org/10.1136/bmjgast-2023-001334

Introduction Randomised controlled trials (RCTs) of key therapies in inflammatory bowel disease (IBD) are often presented and available as abstracts for significant periods of time prior to full publication, often being employed to make strategic and... Read More about Prepublication abstract-only reports compared with full-text manuscripts for randomised controlled trials in inflammatory bowel disease: a systematic review.

A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. (2024)
Journal Article
Noor, N. M., Lee, J. C., Bond, S., Dowling, F., Brezina, B., Patel, K. V., Ahmad, T., Banim, P. J., Berrill, J. W., Cooney, R., De La Revilla Negro, J., de Silva, S., Din, S., Durai, D., Gordon, J. N., Irving, P. M., Johnson, M., Kent, A. J., Kok, K. B., Moran, G. W., …Parkes, M. (2024). A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. The Lancet Gastroenterology & Hepatology, 9(5), 415-427. https://doi.org/10.1016/S2468-1253%2824%2900034-7

Background

Management strategies and clinical outcomes vary substantially in patients newly diagnosed with Crohn's disease. We evaluated the use of a putative prognostic biomarker to guide therapy by assessing outcomes in patients randomised to ei... Read More about A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial..

Infliximab for maintenance of medically-induced remission in Crohn's disease (2024)
Journal Article
Gordon, M., Sinopoulou, V., Sarian, A., Akobeng, A. K., & Moran, G. W. (2024). Infliximab for maintenance of medically-induced remission in Crohn's disease. Cochrane Database of Systematic Reviews, 2(2), Article CD012609. https://doi.org/10.1002/14651858.CD012609.pub2

BACKGROUND: Infliximab is a monoclonal antibody that binds and neutralises tumour necrosis factor-alpha (TNF-α) which is present in high levels in the blood serum, mucosa and stool of patients with Crohn's disease. OBJECTIVES: To determine the effica... Read More about Infliximab for maintenance of medically-induced remission in Crohn's disease.

Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial (2024)
Journal Article
Jairath, V., Zou, G., Wang, Z., Adsul, S., Colombel, J.-F., D’Haens, G. R., Freire, M., Moran, G. W., Peyrin-Biroulet, L., Sandborn, W. J., Sebastian, S., Travis, S., Vermeire, S., Radulescu, G., Sigler, J., Hanžel, J., Ma, C., Sedano, R., McFarlane, S. C., Arya, N., …Feagan, B. G. (2024). Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial. BMJ Open Gastroenterology, 11(1), Article e001218. https://doi.org/10.1136/bmjgast-2023-001218

Introduction: Symptoms, endoscopy and histology have been proposed as therapeutic targets in ulcerative colitis (UC). Observational studies suggest that the achievement of histologic remission may be associated with a lower risk of complications, com... Read More about Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial.

Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial (2024)
Journal Article
Lindsay, J. O., Hind, D., Swaby, L., Berntsson, H., Bradburn, M., Bannur C, U., Byrne, J., Clarke, C., Desoysa, L., Dickins, B., Din, S., Emsley, R., Foulds, G. A., Gribben, J., Hawkey, C., Irving, P. M., Kazmi, M., Lee, E., Loban, A., Lobo, A., …Snowden, J. A. (2024). Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial. The Lancet Gastroenterology & Hepatology, 9(4), 333-345. https://doi.org/10.1016/s2468-1253%2823%2900460-0

Background: A previous controlled trial of autologous haematopoietic stem-cell transplantation (HSCT) in patients with refractory Crohn's disease did not meet its primary endpoint and reported high toxicity. We aimed to assess the safety and efficacy... Read More about Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial.

P556 Immunomodulator and advanced therapies for Induction of clinical remission and response in Crohn’s disease: A systematic review and network meta-analysis (2024)
Journal Article
Sinopoulou, V., Gordon, M., Vuyyuru, S., Darie, A. M., Radford, S., Shale, M., & Moran, G. (2024). P556 Immunomodulator and advanced therapies for Induction of clinical remission and response in Crohn’s disease: A systematic review and network meta-analysis. Journal of Crohn's and Colitis, 18(Supplement_1), i1085. https://doi.org/10.1093/ecco-jcc/jjad212.0686

Background

Several effective advanced therapies have been approved for the treatment of Crohn’s disease (CD) in the past two decades. Many have used synthesis techniques to study this area, but these rarely consider both advanced and immunomodula... Read More about P556 Immunomodulator and advanced therapies for Induction of clinical remission and response in Crohn’s disease: A systematic review and network meta-analysis.